Laura Storoni

USPTO Granted Patents = 14 (Patent Applications = 3)

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 11)

Average Co-Inventor Count = 4.4

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

Cesano Maderno (mb), IT (2019)
Cesano Maderno, IT (2011 - 2024)

Company Filing History:

7 out of 7

Nicox Science Ireland

Merck Sharp + Dohme Corp.

where one patent can have more than one assignee

Years Active: 2011-2024

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11980618 - Nitric oxide releasing phosphodiesterase type 5 inhibitor (2024-05-14),

2. 10610509 - Combinations of prostaglandins and nitric oxide donors (2020-04-07),

3. 10280138 - Nitric oxide donating derivatives of fluprostenol (2019-05-07),

4. 10093696 - Nitric oxide donating carnosine compounds (2018-10-09),

5. 10047047 - Nitric oxide donating derivatives of latanoprost free acid (2018-08-14),

6. 9895335 - Ophthalmic compositions containing a nitric oxide donor (2018-02-20),

7. 9598349 - Quinone based nitric oxide donating compounds for ophthalmic use (2017-03-21),

8. 9446015 - Quinone based nitric oxide donating compounds for ophthalmic use (2016-09-20),

9. 9266820 - Nitric oxide donor compounds (2016-02-23),

10. 9079821 - Quinone based nitric oxide donating compounds (2015-07-14),

11. 9061962 - Quinone based nitric oxide donating compounds (2015-06-23),

12. 8252825 - Angiotensin II receptor antagonists (2012-08-28),

13. 8003811 - Nitric oxide donor compounds (2011-08-23),

14. 7880014 - Angiotensin II receptor antagonists (2011-02-01),

Title: Laura Storoni: Innovator in Pharmaceutical Patents

Introduction: Laura Storoni, an influential inventor based in Cesano Maderno, Italy, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 14 patents, her work primarily focuses on innovative treatments concerning nitric oxide and its applications in medical therapies.

Latest Patents: Among her latest patents, two stand out prominently. The first is a "Nitric oxide releasing phosphodiesterase type 5 inhibitor," which pertains to novel PDE5 inhibitors designed to enhance nitric oxide release, potentially improving treatment options for various conditions. The second patent, "Combinations of prostaglandins and nitric oxide donors," addresses the development of compositions intended for treating glaucoma and elevated ocular pressure, utilizing a nitric oxide releasing isomannide derivative alongside prostaglandin analogs.

Career Highlights: Laura's professional journey includes pivotal roles in notable companies such as Nicox Science Ireland and Nicox S.A. Her dedication to pharmaceutical innovation has positioned her as a key figure in the industry, striving to improve therapeutic outcomes through her inventions.

Collaborations: Throughout her career, Laura has collaborated with esteemed colleagues, including Nicoletta Almirante and Elena Bastia. These partnerships have enhanced her research endeavors and contributed to the successful development of her patented technologies.

Conclusion: Laura Storoni exemplifies the spirit of innovation in the pharmaceutical industry. With her extensive patent portfolio and collaborative spirit, she continues to push the boundaries of medical advancements, aiming to provide better treatment options for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.